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Abstract: The carbohydrate antigens Tn and sialyl-Tn (STn) are expressed in most carcinomas 
and usually absent in healthy tissues. These antigens have been correlated with cancer 
progression and poor prognosis, and associated with immunosuppressive microenvironment. 
Presently they are used in clinical trials as therapeutic vaccination, but with limited success 
due to their low immunogenicity. Alternatively, anti-Tn and/or STn antibodies may be used 
to harness the immune system against tumor cells. Whilst the development of antibodies 
against these antigens had a boost two decades ago for diagnostic use, so far no such antibody 
entered into clinical trials. Possible limitations are the low specificity and efficiency of existing 
antibodies and that novel antibodies are still necessary. The vast array of methodologies 
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available today will allow rapid antibody development and novel formats. Following the 
advent of hybridoma technology, the immortalization of human B cells became a methodology 
to obtain human monoclonal antibodies with better specificity. Advances in molecular 
biology including phage display technology for high throughput screening, transgenic mice 
and more recently molecularly engineered antibodies enhanced the field of antibody production. 
The development of novel antibodies against Tn and STn taking advantage of innovative 
technologies and engineering techniques may result in innovative therapeutic antibodies for 
cancer treatment. 




The deranged expression of glycans is a hallmark of cancer. Glycans such as the Thomsen-Friedenreich 
related antigens, Tn and sialyl-Tn (STn), show a very tumor specific pattern and, in most cancers, they 
are associated with disease progression and patient’s response to treatment. These antigens have 
therefore triggered enthusiasm among the scientific community as diagnostic and prognostic biomarkers. 
A relevant number of antibodies were developed and characterized to be used in immunohistochemistry 
staining protocols. Yet the added value of the identification of STn or Tn as biomarkers has proven 
insufficient, compared to standard protocols, to justify its regular use in clinical practice. A second and 
more pronounced enthusiasm arose with the development of immunotherapies targeting these antigens 
to boost immune responses, i.e., vaccination. Nevertheless, the enthusiasm was rapidly refrained due to 
the unsuccessful results from clinical trials. More recent findings have helped to understand that these 
antigens have potential to dampen immune responses which oblige us to revise the efficacy of immunization 
procedures and to search for more effective strategies for treatment of tumors expressing these antigens. 
Interestingly, the antibodies developed against these antigens have been mainly regarded as tools for 
diagnosis and prognosis. The exploitation of these antibodies as immunotherapeutic tools to elicit  
anti-tumor immune responses has been completely disregarded. Here we revise the efforts built towards 
the development of high affinity antibodies against STn and Tn antigens and the methodologies involved. 
A portfolio of cutting edge methodology is here described that can be used to speed the production of 
more effective antibodies or novel engineered antibody-based molecules as innovative immunotherapies 
against STn or Tn. 
2. Glycosylation in Cancer 
Glycosylation is the most frequent and well-known posttranslational modification of proteins. Glycans 
are present in all living organisms and regulate a diversity of biological processes, including protein 
folding and intracellular trafficking, cell-cell and cell-matrix interactions, cellular differentiations and 
the immune response [1,2]. The relevance of glycosylation is highlighted by the fact that approximately 
1%–2% of human genes are required for glycan biosynthesis, which is catalyzed by the enzymatic 
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reaction of several enzymes that transfer mono or oligosaccharides, i.e., glycosyltransferases, with their 
strict specificity for both donor and acceptor substrates [3]. 
In humans, proteins can be glycosylated with two main types of glycans: N-glycans and O-glycans. 
N-glycans are covalently linked via an amide bond to asparagine in the polypeptide sequence, and it 
usually involves the Asn-X-Ser/Thr (X  Pro) sequence. O-glycans are often covalently linked to the 
hydroxyl group of a serine or threonine into the polypeptide via N-acetylgalactosamine (GalNAc) [4]. 
As glycan biosynthesis is not a template-based process such as DNA, RNA, or protein synthesis, glycan 
expression depends on the balance achieved by the expression and activity levels of the different 
enzymes involved in the glycosylation process, as well as by their localization/organization, for 
instance in the Endoplasmic Reticulum and Golgi apparatus, and on the availability of precursor 
monosaccharide molecules [5]. 
In the mid-1990s there was a peak of interest in glycosylation because a significant correlation 
between certain types of altered glycosylation and cancer prognosis was observed. In fact, aberrant 
glycosylation frequently occurs in cancer and plays a pivotal role in cancer progression, angiogenesis 
and metastasis, cell-cell contact, motility and epithelial-mesenchymal transition (EMT) in cancer cells. 
These alterations of glycosylation comprises under- or over-expression of glycan structures, as well as 
the appearance of novel or truncated structures. However, despite the diversity of glycans at the cell 
surface, only a few distinct structures are associated with malignant transformation and tumor 
progression. This suggests that specific glycosylation patterns contribute to precise mechanisms such as 
gain of function, cell fitness and survival [6]. 
One of the most common aberrant glycosylation in cancer is the neo-expression of  
Thomsen-Friedenreich-related antigens. This family of incomplete O-glycans (Figure 1) includes: The 
Thomsen-nouveau (Tn) antigen (GalNAc-1-O-Ser/Thr), which consists of one residue of GalNAc 
alpha-O-linked to a serine or a threonine residue in the polypeptide chain; the Thomsen-Friedenreich (T) 
antigen (Gal1-3GalNAc-1-O-Ser/Thr) or unmodified core-1 structure, where a residue of galactose 
(Gal) is -linked to GalNAc; the STn antigen, in which the GalNAc residue on Tn antigen is bound to  
a sialic acid (Neu5Ac) on carbon 6; and the sialyl-T (ST), in which the Gal residue on T antigen is bound 
to a Neu5Ac on carbon 3 (Figure 1). The sialylation of both Tn and T antigens blocks the further 
elongation of core-1 structures, with the exception of ST (i.e., monosialyl-T) that can still be converted 
into disialyl-T structure. 
Historically, the T antigen was first identified in 1930 by Thomsen, in collaboration with Friedenreich, 
in a blood sample contaminated by bacteria. Specifically, the action of bacterial neuraminidase released 
the sialic acid that covered the glycan chain, exposing the T antigen on red blood cells, which were then 
recognized by anti-T antibodies present in the sera, causing the subsequent hemagglutination [7]. The 
expression of Tn and STn antigens were later discovered in 1957 by Moreau on subpopulations of blood 
cells characterizing a rare hematological disorder, the Tn syndrome [8]. 
The Thomsen-Friedenreich family antigens have been initially called as oncofetal antigens as they 
are generally precursors in normal complex O-glycan chains [9]. Mainly expressed on epithelial cells, 
the overexpression of these antigens has been reported in several different human tumors, usually  
due to defects in the secretory pathway organelles (Endoplasmic Reticulum and Golgi) and to altered 
glycosyltransferase expression [6]. 




Figure 1. Pathways of Thomsen-Friedenreich antigens biosynthesis. First, GalNAc is transferred 
to a serine or threonine residue in a polypeptide by peptidyl-N-acetylgalactosaminyltransferases 
(GalNAc-T). GalNAc1-Ser/Thr, i.e., the Tn antigen, is then converted by T-synthase to 
Gal1-3GalNAc1-Ser/Thr, i.e., the T antigen or core-1 structure. The Tn antigen can be 
also sialylated by ST6GalNAc-I forming Neu5Ac2-6GalNAc1-Ser/Thr, i.e., the sialyl-Tn. 
GalNAc1-Ser/Thr can also be converted to core-3 structures by the 3GnT-6. T antigen is 
converted to core-2 structures by C2GnT-1, -2, and -3 or can be sialylated by ST3Gal-I, 
originating the sialyl-T antigen. Moreover, sialyl-T antigen can be sialylated by ST6GalNAc-I 
originating disialyl-T antigen. 
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T antigen is overexpressed in breast, colon, pancreas and lung cancer; but it can also be detected in 
up to 40% of normal tissues [4] and in inflamed tissues. Similarly, the ST expression is largely increased 
in some cancers when compared to normal tissues, such as breast and bladder cancer [10–12], but also 
expressed in normal epithelium, many serum proteins and leukocytes [13,14]. In contrast, the Tn and the 
STn antigens show a better cancer associated pattern, with absent or very limited expression in adult 
healthy tissues [15–17], and are therefore more interesting as therapeutic targets. 
2.1. Tn Antigen 
Tn antigen is a pan-carcinoma antigen, expressed on a majority of carcinomas, such as breast, pancreas, 
colon, lung and bladder, being less common in hematological malignancies. In normal tissues, the Tn is 
only expressed in embryonic brain [18] and is shielded in adult tissue. Tn is actually a normal biosynthetic 
precursor of O-glycans however not a normal terminal product, being occasionally observed in adult 
normal cells in the secretory apparatus, but not found on proteins at cell surface or secreted [4,15]. 
Tn is normally extended by the 1,3-galactosyltransferase C1GalT1, also termed T-synthase or core-1 
synthase, or by the core-3 1,3-N-acetylglucosaminetransferase (C3GnT) to form T antigen (core-1) or 
core-3 structure, respectively (Figure 1). In cancer, the loss of T-synthase or C3GnT enzymes may lead 
to overexpression of Tn antigen [19,20]. Altered expression of GalNAc-Ts glycosyltransferases, and  
re-localization from the Golgi to the endoplasmic reticulum, also results in Tn overexpression. In addition, 
defects in Cosmc, a chaperone essential for the activity of C1GalT1, due to epigenetic silencing or 
mutations can also lead to increase expression of Tn antigen in cancer [21,22]. 
Overexpression of Tn antigens promotes cancer cell proliferation and invasiveness. In fact, in breast 
cancer, the accumulation of Tn-bearing proteins in lamellipodia at the cell surface promotes cell 
adhesion, cell motility and invasiveness [23]. Strikingly, the Tn antigen is also detected at early stages 
of tumor development and may serve as a biomarker, since its expression is associated with invasive and 
highly proliferative tumors, and metastasis [24]. 
2.2. Sialyl-Tn Antigen 
Sialyl-Tn is also a pan-carcinoma antigen that is expressed early in tumorigenesis. In contrast to Tn, 
STn is not a normal biosynthetic precursor, meaning that its expression is necessarily pathologic [4].  
As a side note, in some normal tissues, such as colon, the sialic acid residue of STn may be O-acetylated, 
thus masking the STn and therefore its recognition by anti-STn antibodies [25]. No other sugars are 
known to be added to the STn antigen. STn is often co-expressed with Tn and therefore mechanisms that 
result in Tn overexpression likely apply to STn. Specific mechanisms for STn overexpression, include 
ST6GalNAc-I upregulation, or re-localization from the Golgi to the endoplasmic reticulum and also loss 
of O-acetyl groups from STn, have been demonstrated in some cancers [26–29]. 
Specifically, STn expression modulate a malignant phenotype inducing a more aggressive cell 
behavior in gastric and breast carcinoma cells, such as decreased cell-cell aggregation and increased 
extracellular matrix adhesion, migration and invasion [30–33]. 
  
Biomolecules 2015, 5 1788 
 
 
2.3. Pathological Role of Tn and STn in Cancer 
Both Tn and STn antigens have been correlated with cancer progression and poor survival. High 
expression of Tn and STn in human ovarian carcinoma was associated with disease stage, histological 
grade and low overall survival time [34]. In addition, Tn has been shown as good biomarker of invasive 
cervix carcinoma [35]. Moreover, STn expression was associated with invasiveness of liver cancer [36] 
and with lower survival rate in advanced gastric carcinomas [37]. In breast cancer, STn expression was 
associated with lymph node metastasis and high histological grade [38], as well as with resistance to 
adjuvant chemotherapy [39]. STn antigen was also related to high grade tumors, elevated proliferation 
rates and high risk of recurrence and progression in bladder tumors [29]. 
The combination of both features: An acceptable tumor specificity and almost absence of expression 
of Tn and STn in normal cells; together with their association to tumor prognosis and higher malignancy, 
including metastization, turned Tn and STn antigens as excellent targets to be used in therapeutics. 
3. Immune Response and Immunotherapies against Carbohydrates 
The immune response is key not only to elicit protection against pathogens, but also to maintain 
immune surveillance against the development of malignant cells. From this perspective, the development 
of cancer can be seen as a failure of immune surveillance [40]. Most tumor associated carbohydrates do 
not elicit strong humoral responses and, in fact, evidences have shown that their aberrant expression is one 
of the mechanisms developed by cancer cells to prevent effective immune responses against cancer [5]. 
The mechanisms to provide anti-tumor protection can be broadly categorized into the cellular and the 
humoral immune responses. While cellular immune response involve mainly cytotoxic lymphocytes 
such as cytotoxic T cells that may potentially eliminate tumor cells; the humoral response involves  
B cells and the production of antibodies against specific tumor antigens, that ultimately lead to antibody 
dependent cytotoxicity, as mentioned in more detail below. Both arms of the immune response involve 
the activation of a variety of other immune cells, which ultimately converge for both responses. For  
the elicitation of cellular immune responses, antigen presenting cells such as dendritic cells (DCs), 
macrophages and B cells, have to uptake antigens and then present through the major histocompatibility 
complex (MHC) a small portion of peptide antigens (epitopes) to activate both specific CD8+ cytotoxic 
T cells and CD4+ helper T (Th) cells. The receptors of both cytotoxic and Th cells, i.e., T cell receptors 
(TCR), are restricted to recognize peptides, presented in the context of MHC class I or class II, respectively, 
by the antigen presenting cells. The cellular immune response is therefore mainly formatted to fight 
peptide antigens and this may impose a limitation to develop strong immune responses against carbohydrates. 
While it has been reported that cytotoxic T cells may recognize mono- and disaccharides attached to 
peptides with Ser or Thr [41–45], further investigations are necessary to better understand the relevance 
of such recognition in the context of antitumor immune responses. 
The humoral immune response against carbohydrates plays a key role in antitumor responses. In 
contrast to TCR, the B cell receptors (BCR) can recognize directly carbohydrate antigens with no need 
for presentation through MHC. Cross-linking of the antigen on BCR activates B cells, which initiate the 
secretion of IgM antibodies. IgM is the first immunoglobulin isotype to be secreted by plasma B cells 
(effector B cells), characterized by a pentameric structure with relatively low affinity to antigens and 
short time period, as compared with the other isotypes. This process is called the T cell-independent B 
cell activation (Figure 2—upper panel), and is able to provide immunity however with limited duration. 




Figure 2. Simplified depiction of tumor antigen recognition and the induction of humoral 
immune responses. Upper panel—Glycan antigens can be directly recognized by B cells and 
the cross-linking of the B cell receptors lead to IgM secretion through T cell-independent B cell 
activation. Lower panel—Tumor antigens can be endocytosed by antigen presenting cells, 
such as dendritic cells, or B cells and then presented to helper T cells (Th) cells thus leading 
to T cell activation and subsequent T cell-dependent B cell activation. Adapted from [46]. 
For the purposes of long lasting anti-tumor humoral immunity, the production of other antibodies 
isotypes such as IgG is desirable. Physiologically, this usually implies the involvement of Th cells, in a 
process called T cell-dependent B cell activation (Figure 2—lower panel). Th cells specific for particular 
peptides are initially activated by antigen presenting cells. Then carbohydrate specific B cells receive 
stimulatory signals (cytokines) from Th cells, which allow the switching of antibody subtypes from IgM 
to high-affinity IgGs and the differentiation of plasma cells into memory B cells [47]. These high-affinity 
IgG antibodies can bind to the target cancer cells, marking them for destruction by either the complement 
(complement dependent cytotoxicity (CDC)) or by Natural killer (NK) cells (antibody-dependent  
cell-mediated cytotoxicity (ADCC)). 
The knowledge of these physiological mechanisms raised, in recent years, efforts to elicit increased 
immunogenicity of carbohydrate antigens, aiming to generate potent immunotherapies, such as vaccination. 
The approaches to improve carbohydrate immunogenicity include the covalently coupling of carbohydrates 
to immunologically active protein carriers, such as keyhole limpet hemocyanin (KLH) or adjuvants or 
to physiological/pathological carriers, such as mucin 1 protein (MUC1), to guarantee a range of relevant 
epitopes [48]. Interestingly, several studies have demonstrated that the conjugation of glycosylated 
MUC1 peptides with a peptide T helper cell epitope, a Toll-like receptor 2 agonist, tetanus toxoid, or  
a combination of these active protein carriers induces a potent antigenic and cellular immune response 
that can kill the tumor cells and reduce the tumor burden [4,49–53]. 
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Immune Response and Tn/STn Antigens 
There are a relevant number of reports describing immune responses against the Tn or STn antigens. 
For instance, autoantibodies against STn and Tn mucin 1 glycopeptides were identified in breast and 
colorectal cancer patients [54,55]. These autoantibodies were found at higher levels in early stage breast 
cancer patients and associated with reduced metastases rate [54], suggesting a role in inducing antitumor 
immune response. Significantly, these antibodies react with the carbohydrate only when carried on the 
MUC1 protein, emphasizing the role of the peptide backbone in anti-carbohydrate response. A later 
study with a higher patient cohort showed that autoantibodies to MUC1 peptides or glycopeptides could 
not be used for cancer screening [56]. 
Pre-clinical and clinical studies have also shown that immunization with vaccines containing STn or 
Tn usually induces antigen specific antibodies [57–59]. The elicitation of such immune responses after 
vaccination could explain the observed delay in tumor growth in mice and the increased time to 
progression in patients [58,59]. Interestingly, patients receiving the vaccine Theratope, which consisted 
of STn anchored to the KLH, developed anti-STn antibodies, whose abundance was directly correlated 
with disease free survival [60]. However, the observed immune responses against STn and Tn antigens, 
seem to be insufficiently robust to induce protective immune responses. In fact, in spite of the fact that 
STn and/or Tn-based cancer vaccines have already entered clinical trials (NCT00030823) including the 
case of Theratope that reached Phase III (NCT00046371) [58], no vaccine has been approved for clinical 
use yet. Most tested vaccines failed to induce robust T cell-mediated immunity and did not bring any 
survival benefit for patients. A better understanding of the immune response against these antigens is 
advised to elicit increased immunogenicity to improve potency of immunotherapeutic approaches. 
In recent years, a better understanding of the immunomodulation role of the Tn and STn antigens has 
elucidated their contribution to immune tolerance, thus explaining in part the failure with vaccination 
protocols. For example, Tn antigen expressed in mucin 6 (MUC6) protein abrogates Th1 cell responses 
and promotes interleukin 17 (IL-17) response, which might favor immune escape of tumor cells [61]. 
Moreover, Tn is recognized by the tolerogenic lectin—macrophage galactose C-type lectin (MGL), 
expressed by DCs and macrophages, which endows these cells to suppress T cell immunity, thus playing 
a role in tumor progression [62]. 
The overexpression of STn is associated with low infiltration of nest CD8+ lymphocytes in 
endometrial cancer [63]. Furthermore, STn present in secreted colon cancer mucins can interact with 
CD22 and down-modulate B cell signal transduction [64]. Moreover, siglec-15 recognizes the STn 
antigen expressed by cancer cells and transduces a signal for enhanced transforming growth factor beta 
(TGF-) secretion in tumor-associated macrophages, which can contribute to tumor progression by  
the TGF--mediated modulation of intratumoral microenvironment [65]. More recently, our group 
demonstrated that STn-expressing cancer cells impair maturation of DCs, endowing a tolerogenic  
function and therefore limiting their capacity to trigger protective anti-tumor T cell responses [66].  
We have also observed that blockade of STn antigens expressed by cancer cells was able to lower  
the induction of tolerance in vitro and DCs become more mature [66]. These findings suggest that 
targeted therapies based on antibodies may provide efficient means to enhance immune responses  
against STn tumor cells. 
  




For the last 20 years, monoclonal antibody-based treatment has been one of the most successful 
therapeutic strategies in different fields, including cancer. Due to their unique features, such as high 
specificity and engagement with the immune system, antibodies’ impact has been recognized in many 
therapeutic areas [67,68]. The unceasing development and optimization of methods involved in antibodies 
engineering, production and purification, as well as the increasing knowledge of the interplay between 
antibodies, cancer cells and immune system have contributed to the development of innovative next 
generation antibodies which are more effective, safer and with broader applications [69–71]. Nowadays, 
the market for therapeutic antibodies has been growing significantly within the healthcare industry so 
that 40 years after the generation of the first monoclonal antibody (mAb) [72], around 47 recombinant 
monoclonal antibody products have been approved in the United States or Europe for the treatment of  
a wide variety of diseases, ranging from cancer to infectious and cardiovascular diseases to autoimmune 
diseases [73,74]. 
4.1. Structure and Role of Antibodies 
Antibodies are glycoprotein molecules with a remarkable ability to recognize and bind to antigens 
with high affinity and specificity, thus further promoting their inactivation or elimination [68]. Typically, 
antibodies (or immunoglobulins (Igs)) are composed of two antigen-binding fragments (Fab) linked via 
a flexible region (hinge region) to a constant (Fc) region (Figure 3). Antigen specificity is conferred by the 
antigen binding site of the antibody, which is formed by the hypervariable complementarity-determining 
regions (CDRs) on the variable regions of each heavy and light chain, present in the Fab portions.  
On the other hand, the Fc region is responsible for immune effector functions of the antibodies, 
promoting the binding to various effector molecules and cells of the immune system [75,76]. 
Antibodies’ mechanism of action involves ADCC, CDC, or blockage of the action of specific molecules. 
Additionally, antibodies can also function as signaling molecules [77]. Specifically, ADCC is an effector 
mechanism in which antibodies direct NK cells to kill antigen-expressing cells. This mechanism relies 
on the engagement of Fc receptors expressed by NK cells leading to their activation and exocytosis of 
the cytolytic granule complex perforin/granzyme, resulting in the destruction of target cells  
by apoptosis [78]. CDC, also known as the classical pathway of the complement system, is a cytolytic 
cascade mediated by a series of complement proteins (C1–C9) that are abundantly present in the serum. 
It starts with the binding of the complement molecule, C1q, to the Fc domain of the antibody (IgG or 
IgM) bound on the surface of the target cell [77]. This triggers the subsequent complement cascade that 
leads to the lysis of target cells. Antibodies can also present a blocking activity, which prevents growth 
factors, cytokines and other soluble mediators from reaching their target receptors [75]. Finally, 
antibodies can induce the crosslinking of receptors that are connected to mediators of cell apoptosis, 
such as caspases, leading to cell death [79]. Antibodies that retain these functions represent an important 
therapeutic strategy in many different fields. 




Figure 3. Schematic representation of an immunoglobulin G (IgG) mAb structure. The IgG 
molecule is composed by constant (C) and variable (V) domains for each light (L) or heavy 
(H) chain. The heavy chain comprises three constant domains (CH) and one variable (VH), 
and the light chain contains one constant (CL) and one variable (VL) domain. This molecule 
can be divided into Fc and Fab regions in which the latter includes the variable regions, called 
complementarity-determining regions (CDRs). 
4.2. Therapeutic Antibodies in Cancer 
Therapeutic antibodies are now one of the most successful and important strategies for treating cancer 
patients. In their early years, therapeutic antibodies were derived from murine or based on a mouse antibody 
amino acid sequence, which led to potential issues concerning the generation of human anti-mouse 
antibodies resulting in immunogenicity or allergic-like reactions. The use of murine antibodies also has 
the problem of low Fc effector function since murine Fc region are not correctly recognized by human 
Fc receptors. This results in low efficiency in recruiting the human immune system, including ADCC 
and CDC, which prevents the effective use of murine antibodies in therapy. In alternative, the next 
generation of therapeutic antibodies involved genetically engineered fusion of mouse variable with 
human constant domains, which resulted in a more favorable safety profile and half-life, while retaining 
the specificity of murine antibodies [80]. 
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Therapeutic antibodies can function through mediating alterations in antigen or receptor functions, 
modulating the immune system or delivering a specific drug that is conjugated to an antibody that targets 
a specific antigen. Nowadays, there are molecular techniques that can alter antibody effector function, 
size and immunogenicity contributing to the development of new and more effective antibody-based 
therapies [81]. 
Therapeutic antibodies can kill tumor cells by several mechanisms, by direct action of the antibody, 
which includes: The blocking of receptors or agonist activity; induction of apoptosis or delivery of a drug 
or cytotoxic agent; or immune-mediated cell killing mechanisms, which involves CDC, ADCC, and 
induction of phagocytosis (Figure 4). Furthermore, T cells activation can be improved by antibody-mediated 
targeting and further cross-presentation of antigen to DCs, T cells targeting to the tumor is improved by 
antibody-mediated blockade of T cell inhibitory check points (e.g., CTLA4 and PD1) are also among 
the strategies for tumor cell elimination. All of these approaches have been successfully applied  
in the clinic [82–85]. 
 
Figure 4. Main functions of therapeutic mAb. mAb can induce antibody dependent  
cell-mediated cytotoxicity (ADCC) by inducing the release of cytotoxic granules in effector 
cells (e.g., NK cells). It can also induce complement dependent cytotoxicity (CDC), which 
starts with the binding of C1q to the antibody triggering the complement cascade. mAb can 
induce apoptosis as well by activating caspases. In addition, mAb can block receptor/ligand 
interactions preventing signaling cascade activation, as well as specifically deliver drugs  
into tumor cells. 
Particularly, the target antigen of therapeutic antibodies should be expressed on the surface of cancer 
cells and be abundant and accessible to antibodies. Depending on the desired mechanisms of action, 
therapeutic antibodies could be quickly internalized, in case of delivery of toxins into cancer cells and 
downregulation of cell surface receptors. On the other hand, in ADCC and CDC they should remain on 
the cell’s surface since the Fc region should be available to immune cells and complement proteins [81]. 
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5. Therapeutic Antibodies against Tn and STn Antigens 
Due to the association of the Tn and STn antigens with several types of cancers as well as to tumor 
progression and metastasis, efforts have been made to develop antibodies against these glycosylated 
structures. In addition, the fact that cancer patients are able to produce autoantibodies, prompted its use 
as biomarkers for early detection of cancer [86] or response to therapy. Interestingly, antibodies found 
in cancer patients have not proven to be efficient in activating the immune system and eliminating  
the malignant cells. Therefore, it is essential to produce more effective antibodies that will specifically 
kill cancer cells. 
So far, the majority of the existent antibodies were obtained by hybridoma technology. Since the 
development of the first anti-STn specific mAb in 1981, named B72.3 [87], more antibodies against STn 
antigen have been produced. During this quest, different immunogens and techniques were used and 
these lead to the development of antibodies exhibiting different affinities and specificities towards the 
STn antigen [46]. The B72.3 mAb was generated following immunization of mice with membrane-enriched 
fraction of human breast carcinoma cells and found to react with TAG-72, a glycoprotein with mucin-like 
characteristics, and with ovine submaxillary mucin (OSM), which is rich in STn epitopes [87,88]. The 
second generation antibody CC49 was generated following immunization of mice with B72.3 affinity 
purified TAG-72 molecules [89]. Further studies have been developed using this antibody and its humanized 
format, which is currently undergoing a clinical trial for its use in radioimmunoguided surgery. However 
the fine specificity of these mAbs is unclear and in addition to bind to STn, CC49 also recognize other 
glycans. TKH2 [90] and HB-STn1 are two other anti-STn mAbs that were generated by immunization 
of mice with OSM [88]. Ogata and colleagues reported that B72.3 strongly binds glycoproteins bearing 
STn-trimers, but poorly interacts with monomeric-STn glycoproteins [91]. This raised the question of 
STn configurations for antibody recognition. Later, the antibody MLS102 generated by immunization 
of mice with LS 180 colonic cancer cells was reported to be specific for clustered STn [92]. More 
recently, novel anti-STn antibodies LLU9B4 and 3P9 have been produced. The first was generated by 
immunization of mice with STn glycoproteins extracted from human colon adenocarcinoma cell line 
LS174T [93] and 3P9 was obtained using human colorectal adenocarcinoma SW1116 cells to immunize 
mice [94]. This last mentioned antibody is particularly interesting since it is an IgM mAb that showed 
significant inhibitory effect on proliferation and migration of STn expressing cells and tumor growth by 
inducing apoptosis. These results suggested that 3P9 mAb has potential applications, not only in diagnosis 
and imaging, as reported for most of the previous mentioned antibodies, but also for antibody-based 
tumor therapy [94]. 
Several mAbs with different specificities towards the Tn antigen have also been generated using 
different immunogens. Some of these antibodies are CU-1 [95], MLS 128 [96], BRIC 66 (IgM) and 
BRIC 111 (IgG1) [97], PMH1 [98], and more recently the mAbs KM3413 [99], 2154F12A4 [100] and 
GOD3-2C4. Monoclonal antibodies, such as MLS128, KM3413 and GOD3-2C4 have been shown to 
have a therapeutic potential due to their ability to inhibit the growth of certain cancer cell lines [101], 
and particularly limit the growth of a xenografts of a human lung carcinoma, in the case of the mAb 
GOD3-2C4 [102]. 
While most of these antibodies are promising, their specificity is still debatable and the potential 
therapeutic effect on cancer cells and patient tissues needs to be thoroughly assessed prior to their use as 
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therapeutic agents. A widely used technique to characterize an antibody’s specificity is Enzyme-linked 
immunosorbent assay (ELISA) and many variations of this methodology against glycoconjugates that 
are immobilized in plastic or alternatively coating plates with the antibodies. However, in most cases the 
glycan antigens may not be available and the interpretation is difficult. Therefore, there is still the need 
to develop assays that fully characterize this specificity of anti-carbohydrate antibodies. Recent efforts 
in this regard have been accomplished with the development of glycan microarray technologies, which 
allow the study of interactions between antibodies with carbohydrates in a high-throughput manner [103]. 
Additionally, existing antibodies are carbohydrate reactive antibodies, meaning that they react with any 
glycoprotein carrying the glycan. Only a few were able to recognize glycan/peptide epitopes [104] 
though with low affinity. Antibodies to promising STn or Tn glycopeptide epitopes expressed by cell 
surface glycoproteins would improve specificity and avoid binding to irrelevant extracellular glycoproteins, 
such as mucins, which may deceive effective binding of antibodies to cell surface. 
5.1. Antibody Production 
The urge for therapeutic application of antibodies allied to advances and innovation in molecular 
biology throughout the years allowed for the development of several methods for mAb production. These 
technologies endorsed the generation of antibodies against virtually any target molecule on human cells 
allowing their particular employment in cancer therapeutics. Initially, mAbs production was exclusively 
accomplished using the hybridoma technology [72] and B cell immortalization using Epstein-Barr virus 
(EBV) [105]. A few years later, the development of alternative methods such as immunization of 
transgenic mice expressing human Ig loci [106] and phage display [107] enabled further progress with the 
production of fully human antibodies. 
5.1.1. Hybridoma Technology 
Hybridoma technology has long been a remarkable and indispensable tool for generating high-quality 
mAbs. It allows the isolation and production of mAb with high affinity and specificity against soluble 
or membrane-bound antigens using an animal’s immune system [108,109]. This technology was developed 
in 1975 by Kohler and Milstein [72], who received a Nobel Prize for this achievement, in which the 
production of antibodies by spleen B cells obtained from immunized mice was immortalized by fusion 
with cancerous myeloma cells (Figure 5) [110,111]. The initial step in mAbs production by hybridoma 
technology is stimulation of the immune system of a suitable host, normally a mouse, with the desired 
antigen. Usually, the antigen is mixed with an adjuvant to enhance the immune response and consequently 
increase antibody production. After immunization, antibody-secreting B cells are isolated from the 
mouse spleen and fused, by using polyethylene glycol (PEG) with an immortalized immunoglobulin 
non-secreting myeloma cell line that lacks the hypoxanthine-guanine-phosphoribosyltransferase (HGPRT) 
gene. These cells are then cultured in hypoxanthine-aminopterin-thymidine (HAT) selection medium in 
which only the hybridoma cells are able to survive and proliferate since they have inherited immortality 
of myeloma cells and selective resistance of B cells to survive in medium with aminopterin. Usually, the 
screening of the desired antibody-producing cells is performed using techniques such as ELISA, Western 
Blot and flow cytometry to analyze the reactivity of their culture supernatant. Positive hybridoma cells 
are further grown and cloned so high amounts of mAbs can thus be produced in vitro [74,112–114]. 
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Several technical improvements have been accomplished to solve the troublesome of this technique, 
namely, the immortalization of mice B cells and development of different partner cells for fusion; use of 
feeder layers to increase hybridoma survival and stability in culture and use of different methods for cell 
fusion, namely electrofusion [110,115]. 
The first antibody to be approved for the market, muromonab-CD3, was an unmodified murine antibody 
developed using the hybridoma technology [116]. However, murine mAbs cause immune reactivity 
when applied to humans and also have low Fc effector function due to the inefficient recognition of their 
Fc region by human Fc receptors, thus limiting their applications in therapeutics [74]. Consequently, the 
use and production of human mAbs was boosted in a way that alternative methods have been studied 
and developed, such as immunization of transgenic mice expressing human Ig loci, phage display 
libraries, and humanization of mouse antibodies via genetic engineering [106,117,118]. 
 
Figure 5. Schematic representation of the hybridoma technology. This technology involves 
the initial step of mice immunization with desired antigen, followed by the recovery of  
B cells from mice spleen and consequent fusion with myeloma cells. After that, hybridoma 
cells are selected in HAT medium and clones are screened according to the reactivity of their 
supernatants against the antigen. Finally, the selected clones are further cloned and expanded 
in order to obtain monoclonal antibodies with the desired specificity. 
5.1.2. B Cell Immortalization 
Soon after the introduction of the hybridoma technology, an alternative approach to obtain stable 
human antibody producing B cell lines was created in which antigen-specific plasma B cells are 
immortalized using the Epstein-Barr virus (EBV) [119]. This virus belongs to the herpes family and has 
the ability to efficiently immortalize in vitro nearly all human B cells. Due to the low frequency of 
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antigen-specific B cells among peripheral blood lymphocytes of donors, the cells expressing the desired 
antibody on their surface need to be selected. After selection, target specific B cells are infected with EBV. 
The B cells are transformed into immortalized diploid cells that usually do not release the virus particles 
and preserve the characteristics of the initially infected B cells, meaning that they are able to continuously 
produce and secrete the desirable antibodies [120]. The antibodies produced by this method represent 
the antibody repertoire of the lymphocytes’ donor and, when using a patient’s B cells, it offers the possibility 
of obtaining antibodies with unique specificity against neoantigens. However, the EBV-transformed 
cells cannot grow indeterminately since they do not have the phenotype of malignant cells. In addition, 
these cells are difficult to clone, and usually produce only low yields of immunoglobulins [119,120]. In 
this way, improvements to this method have been carried out, namely fusion of the EBV-immortalized 
antibody secreting cells with appropriate heterohybridoma fusion partners, which promoted increased 
stability and higher amount of secreted antibodies [121]. This technique has been successfully applied 
to generate antibodies against several antigens, such as proteins and carbohydrates [122,123], but never  
against STn and Tn. 
5.1.3. Phage Display Technology 
The main struggle in traditional methods is the development of fully human mAbs to apply in 
therapeutics and consequently, several efforts have been endeavored to overcome this problem. The 
debut of recombinant DNA technology together with progress of in vitro technologies provided several 
new and powerful ways that lead to the development of the phage display technology to create 
therapeutic antibodies. This ground breaking technology was introduced in 1985 by Smith [107] centered 
on the selection of a particular phenotype (e.g., a ligand specific to a target antigen) from repertoires of 
molecules displayed on phages. In 1990, McCafferty and colleagues demonstrated that the display of 
antibody fragments on phages was conceivable through the use of vectors to introduce antibody DNA 
into phage genomes, thus combining genotype and phenotype in one phage particle [117,124]. The 
concept behind this display technology is that a large library of potentially interesting antibodies is 
created, from which antibody fragments with desirable specificity and affinity can be selected against  
a specific antigen [125]. The use of phage libraries carrying human Ig genes-antibody display libraries was 
one of the most successful applications of this approach [125]. 
For the construction of an antibody library, the repertoire of V-genes encoding antibodies from B 
cells is amplified via PCR using a set of specific primers covering all the V gene families. Subsequently 
the antibody fragments are generated by random combination of VL and VH chain genes [126,127]. 
Based on the origin of antibody genes, the libraries can be categorized into natural or synthetic. 
Furthermore, natural source repertoire libraries can be either naive or immune. Naive libraries are derived 
from non-immunized donors of B cells, and immune libraries are derived from different kinds of 
immunized animals, human patients with a certain disease or previously exposed [75]. Additionally, 
several formats of antibody fragments, most commonly Fab and scFv can be cloned and displayed on 
phage libraries [128]. Once created the repertoire of antibody fragments, this heterogeneous mixture of 
phage clones is then screened by an affinity selection process called panning, during which the phage 
populations are presented to specific targets in order to select specific target-binding phages (Figure 6). 
The antigen of interest is immobilized on a solid support and the antibody phage library is applied to 
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promote the binding of specific phages against the selected antigen. Extensive washes are performed to 
remove unbound phages which do not display specificity against the target antigen. Positive binding 
phages are then eluted and amplified through bacterial infection and grown to produce high phage titer 
and use in further rounds of selection. Typically, several rounds of panning are performed (2 to 5 rounds) 
in order to progressively enrich the phage pool with specific binding phages. Antibodies specific for the 
desired antigen are usually identified by ELISA by screening a set of random clones that were chosen to 
be analyzed [125,129]. 
 
Figure 6. Schematic representation of the phage display technology. This technique includes 
three main steps that begin with antibody phage library construction and antibody fragments’ 
display onto the phage surface, followed by several rounds of selection against the target 
antigen (termed panning cycle) and lastly, clone isolation and subsequent screening for 
fragments with desired specificity. 
Once antibody fragments of interest are isolated, due to the link established in phage display between 
genotype and phenotype, the sequence encoding these molecules can be promptly determined and used 
to produce the desired antibodies, as well as to refine the isolated antibodies’ properties [125,130]. Currently, 
there are three antibodies on the market created using the phage display technology Humira [131], 
Benlysta [132], and AbThrax [133]. Particularly, research using this technology has been making 
progress on the production of antibodies against challenging antigens, namely tumor associated 
carbohydrates. In particular, this strategy can be an alternative to conventional hybridoma technology, 
especially when aiming to obtain antibodies against simple and small conformational antigens, with 
low immunogenicity [134]. Kubota and colleagues have successfully used the antibody phage display 
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technology to identify an anti-Tn scFv antibody [135]. This was reformatted into a human IgG with 
promise for therapy, since it has been proven to bind specifically to Tn-positive tumor cells and to induce 
significant cytotoxic activity in ADCC experiments. Moreover, in comparison with wild-type IgG 
molecules, the scFv-Fc format has potential benefits for therapeutic development and use. These types 
of antibodies have small molecular weight and therefore are thought to have better tissue penetration. In 
addition, since they are composed of a single polypeptide chain, heteromeric disulfide association is not 
required and consequently, expression of functional scFv-Fcs has been reported using yeast [135]. 
5.1.4. Transgenic Mice 
Among the several techniques developed to produce human mAbs, recently a technology focused its 
efforts on the generation of low immunogenic mAbs using transgenic mice expressing repertoires of 
human antibody gene sequences. The production of human mAbs using the hybridoma technology and 
genetically engineered mice expressing human antibody repertoires was first reported in 1994 [136]. The 
engineered mice were generated through the disruption of the endogenous mouse Ig-heavy chain and 
Ig-light chain loci to avoid the expression of mouse heavy or light chains. Simultaneously, in order to 
replace the mouse chains, transgenes encoding human Ig-heavy chain and Ig-light chain were introduced. 
Upon immunization, these knockout/knockin mice were able to produce human antibodies and using 
conventional hybridoma technology, the spleens were further used in the production of human mAbs by 
hybridoma cell lines [136]. 
Over the past years, progress has been accomplished and additional V gene segments can be expressed 
by transgenic mice expanding the repertoire of the antibodies obtained. Currently, several different 
versions of similarly engineered mice have been developed and exploited by different biotechnological 
and pharmaceutical companies. In fact, over 50 human mAbs developed using this technology are in 
clinical trials and by 2010 six indeed reached the market [119]. 
5.1.5. Molecularly Engineered Antibodies 
The expansion of therapeutic antibodies is a dynamic field that evolves alongside with technological 
developments. Advances in antibody engineering allowed to overcome the main problems associated 
with the immune response developed against foreign antibodies introduced into humans [137]. Antibody 
chimerization, humanization and the development of human antibodies were the major strategies 
adopted to reduce immunogenicity [68]. Additionally, efforts to improve affinity, pharmacokinetics and 
avidity of therapeutic antibodies as well as enhance their natural effector functions have been employed. 
Several approaches can be used to manipulate the variable regions in order to increase the binding 
affinity for antigens, or tune the binding specificity, namely chain-shuffling, randomization of CDRs 
and induced mutations in the variable regions [138,139]. On the other hand, modifications in glycosylation 
or amino acid sequences in the constant region can modulate the Fc effector functions of antibodies, 
since this region is involved in ADCC and CDC [137,139]. Extension of the IgG half-life in serum is 
accomplished by engineering the Fc region particularly in modulation of its interaction with the neonatal 
Fc receptor (FcRn) which is associated with immunoglobulin protection from intracellular degradation [140]. 
Currently, antibody-drug conjugates, multimerization of antibody fragments and production of a variety 
of formats not found in nature, such as Fab and scFv fragments, diabodies and minibodies are rapidly 
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emerging as key strategies in the antibody engineering field [141,142]. As anticipated, antibody engineering 
has been fostering continuous research and developments in the refinement and manufacturing of 
innovative antibodies that display new and enhanced properties to stimulate the antitumor immune 
response and be applied in therapeutics. 
6. Conclusions 
Antibodies against STn and Tn antigens have initially raised a great interest due to their potential use 
as diagnostic tools. This interest was further extended to the exploitation of the antibodies’ predictive 
value in vaccinated patients. Unexpectedly, there has been no (or very limited) efforts in extending the 
therapeutic use of antibodies to boost antitumor immune responses or conjugated to toxic payloads. The 
fact that no therapeutic antibodies have entered into clinical trials could be explained by an apparent lack 
of interest given the glaring promise of vaccination or by an interlude while new antibodies are being 
developed by academic or biopharmaceutical companies. Undeniably, there is the need to develop novel 
antibodies with improved specificities targeting STn or Tn. Alternatively, antibodies against glycopeptides 
could be a suitable approach to increase their specificity. Obtaining antibodies with such specificity for 
the glycan conformation is technically demanding, therefore novel cutting-edge methodologies herein 
described emerge as very attractive resources to accelerate the development of therapeutic anti-Tn and -STn 
antibodies that could be particularly useful in enhancing immune responses or as drug delivery systems. 
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